ClinicalTrials.gg
RecruitingNCT06706362Updated Oct 13, 2026

Assessing the Utility of Prophylactic Antibiotics at Time of Urethral Bulking Using Bulkamid (Bulkamid Study)

A Phase 4 interventional study of Bactrim or Macrobid and Placebo in Stress Urinary Incontinence, sponsored by Ohio State University. Recruiting at 1 site in United States. Open to female participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by Ohio State University · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
138
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 190 studies in Urinary Incontinence, Stress with a site in United States — 28 open to participants now, 41 under way, 4 of them phase 3. Urinary Incontinence, Stress · United States.

Planned enrollment
65th of 164
138 · median 99
Started
2025
with 12 others
Phase 4
15 of 190
3 open now
Primary completion
2027-04
later than 19 of 40 live
Registered
173rd of 190
by date

Among the 190 studies in Urinary Incontinence, Stress with a site in United States, this one is the 65th largest by planned enrollment of the 164 interventional ones that give a count, is one of 13 that started in 2025, is one of 15 in phase 4, reaches primary completion later than 19 of the 40 other live ones, and was the 173rd registered.

Urinary Incontinence, Stress

655 studies on the registry are indexed under Urinary Incontinence, Stress; 123 are open to participants now.

Browse Urinary Incontinence, Stress studies →

Open to participants now

28 of the 190 studies in Urinary Incontinence, Stress with a site in United States are open now. Recruiting first, the newest first:

22 more — sign in →

All 28 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 76 Urinary Incontinence, Stress studies recruiting now, 43 (57%) set no upper age limit and 18 (24%) stop at 75 or younger; 2 take children under 18; 16 take healthy volunteers.

This study: 18 Years to 50 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 190 studies in Urinary Incontinence, Stress with a site in United States, or all of them as a file.
02

Study summary

The primary aim of this study is to assess the utility of prophylactic oral antibiotics at time of Bulkamid transurethral bulking to reduce the incidence of urinary tract infection (UTI) in the immediate postoperative period. The secondary aims of the study include assessing UTI rates and success rates if patients require temporary indwelling catheter versus intermittent self-catheterization (ISC).

Read the detailed description

Specific Aim 1: To determine if receiving prophylactic oral antibiotics at time of urethral bulking reduces the risk of post-operative urinary tract infection (UTI).

Patients will be randomized and blinded into two arms: oral antibiotic versus placebo. Patients will receive either the placebo pill or oral antibiotic in the pre-operative holding area prior to their procedure. Oral antibiotics will include trimethoprim/sulfamethoxazole (Bactrim, first line) or nitrofurantoin (Macrobid, second line), determined by patient allergies.

Specific Aim 2: To assess if factors such as patient discharge with ISC/indwelling foley or number of Bulkamid injection sites is correlated to improvement in Stress urinary incontinence (SUI) at 6 weeks postoperatively and at one year postoperatively.

Patients will complete a brief survey preoperative, at 6 weeks postoperatively after their procedure, and at 1 year postoperatively after their procedure. The survey will consist of prior validated urogynecologic surveys including the Pelvic Floor Disability Index/Urinary Distress Inventory (PFDI/UDI- 6) and the MESA questionnaires as well as an extended VAS scale to evaluate global improvement.

Specific Aim 3: To discern if any patient characteristics are associated with higher patient satisfaction following the procedure.

03

Conditions studied

  • Stress Urinary Incontinence

Keywords

  • Bulkamid
  • Urinary tract infections
  • Bactrim
  • Macrobid
  • Urethral bulking
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients evaluated by a pelvic floor specialist (either urogynecologist or urologist) at The Ohio State University with plans to undergo urethral bulking with Bulkamid for stress urinary incontinence or mixed urinary incontinence (stress predominant).
  • Negative testing for UTI in pre-operative work-up (including either negative urine culture or urine dip negative for infection).
  • Office evaluation with evidence of SUI either with urodynamic studies (UDS) or positive cough stress test (CST).
  • Post-void residual volume of 150 mL or less (measured by either catheterization or bladder scan)

Exclusion criteria

Exclusion Criteria

  • to both oral antibiotics including antibiotic allergies or significant renal disease
  • Patient undergoing additional pelvic organ prolapse procedures or other urologic procedures concomitantly
  • Recurrent UTIs, defined as 3 or more UTIs within the past 12 months or 2 UTIs within the past 6 months
  • Patients currently taking daily antibiotic prophylaxis for any reason
  • Non-English speaking patients
  • Pregnant patients
  • Pelvic organ prolapse stage greater than 2
  • Patients with due to underlying medical conditions
  • Recent antibiotic treatment within one week of the procedure
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
138 participants (estimated)

Study arms

  • Active comparator
    Bactrim or Macrobid (single dose)

    Bactrim (800/160mg) or Macrobid (100 mg) depending on participants' allergies

    Drug: Bactrim or Macrobid

  • Placebo comparator
    Placebo

    Identical appearing placebo for a single dose

    Drug: Placebo

Interventions

  • DrugBactrim or Macrobid

    Participants will be assigned to Bactrim or Macrobid depending on participants' allergies

  • DrugPlacebo

    Participants will be assigned to identical appearing placebo

06

What researchers measure

Primary outcomes

  1. Risk of post operative urinary tract infections (UTI)

    Intervention (pre-operative oral antibiotics) and placebo groups will be compared for the risk of post-operative UTIs following urethral bulking procedures performed in the operating room. Patients who have symptoms, concerning for UTI during the immediate 6 week postoperative period will be asked to give a urine sample for culture. UTIs which are culture proven and symptomatic will be treated per individual provider preference. Positive urine cultures will be defined as cultures with greater than 50,000 CFU for voided specimens and greater than 5,000 CFU for catheter specimens. If a patient's urine culture is positive for mixed flora and cannot be speciated further by our microbiology laboratory, they will be asked to present for a straight catheter specimen in the office for definitive diagnosis; this is an established protocol which is already standard in our practice. All positive cultures during this time period will be recorded.

    Time frame: 6 weeks after the procedure

Secondary outcomes

  1. Drug Use and Side Effects

    Assessing if factors such as patient discharge with Intermittent self-catheterization (ISC)/indwelling foley or number of Bulkamid injection sites is correlated to improvement in SUI at 6 weeks and 1 year postoperatively.

    Time frame: 6 weeks and 1 year after the procedure, up to 1 year

  2. Effects on higher patient satisfaction

    If any patient characteristics are associated with higher patient satisfaction following the procedure. Following the procedure, patients will be asked to complete a survey compromising of the Pelvic Floor Disability Index/Urinary Distress Inventory - Short Form (PFDI/UDI-6), the MESA questionnaire and an extended Visual Analogue Scale (VAS; scale of 0 or extremely unsatisfied to 100 or extremely satisfied). Patients will be given a paper copy of the survey at their 6 week post-operative appointment as well as an online link to complete the survey. This same survey will then be administered again approximately 1 year after the patient's procedure.

    Time frame: 6 weeks and 1 year after the procedure, up to 1 year

07

Study locations

1 of 1 sites recruiting
  • The Ohio State University Wexner Medical Center OB/GYN Female Pelvic Medicine and Reconstructive Surgery
    Columbus, Ohio 43210, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2025 (actual). Primary completion is estimated for Apr 2027, 19 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 11, 2024
First posted
Nov 26, 2024
StartActual
Sep 15, 2025
Primary completionEst.
Apr 15, 2027
CompletionEst.
Oct 15, 2027
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06706362
Responsible party
Susanne Taege (MD, Assistant Professor, Ohio State University) — Principal investigator
First posted
Nov 26, 2024
Start date
Sep 15, 2025
Primary completion
Apr 15, 2027 (estimated)
Completion
Oct 15, 2027 (estimated)
Last update
Oct 13, 2026

Study contacts

Susanne Taege, MD
Contact
Susanne.Taege@osumc.edu
614-293-4643
Shirley Dong, MD
Contact
Shirley.Dong@osumc.edu
614-293-8045
Susanne Taege, MD
principal investigator · Ohio State University

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion